32 recruiting, 24 completed, 23 terminated, 23 unknown. 52 Phase 2, 40 Phase 1, 15 Phase 3, 12 Not applicable.
Follow Small-cell Lung Cancer: new trials by email Literature Review of Small-cell Lung Cancer trials Research Report on Small-cell Lung Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SCLC Tarlatamab Blood Collection Small-cell Lung Cancer | Not yet recruiting | Duke University | 25 | 2026-10-01 | 2026-08-05 | |
| BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01) BL-M14D1 and Atezolizumab, Carboplatin+ Etoposide + Atezolizumab followed by Atezolizumab and Lurbinectedin - Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer | Phase 3 | Recruiting | SystImmune Inc. | 550 | 2026-08-04 | 2026-10-15 |
| DSP-0390 in Combination With Atezolizumab for Small Cell Lung Cancer DSP-0390, Atezolizumab - Small-cell Lung Cancer, Small Cell Lung Cancer Extensive Stage | Phase 1 | Recruiting | Washington University School of Medicine | 20 | 2026-08-03 | 2026-08-04 |
| A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors HH160 - Solid Tumor, Non-small Cell Lung Cancer | Phase 1 | Recruiting | Huahui Health | 299 | 2026-06-11 | 2026-08-21 |
| Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial) Cirtuvivint, Irinotecan - Small-cell Lung Cancer, Small Cell Lung Carcinoma | Phase 1 / Phase 2 | Recruiting | Washington University School of Medicine | 42 | 2025-12-18 | 2026-08-12 |
| Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer ZG006, Topotecan - Small-cell Lung Cancer | Phase 3 | Recruiting | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 420 | 2025-12-12 | 2026-01-05 |
| A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE) ZL-1310, Investigator's Choice of Therapy - Small-cell Lung Cancer | Phase 3 | Recruiting | Zai Lab (Shanghai) Co., Ltd. | 480 | 2025-11-30 | 2026-10-16 |
| 7T Brain MRI Scan for Micro-brain Metastasis (microBM) Detection for Patients With Small-cell Lung Cancer (SCLC), Who Decline Prophylactic Cranial Irradiation (PCI) 7t MRI - Small-cell Lung Cancer, Brain Metastases | Recruiting | University of Missouri-Columbia | 20 | 2025-11-01 | 2025-12-02 | |
| A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer IDE849, durvalumab, IDE161 - Small-cell Lung Cancer, Neuroendocrine Carcinomas | Phase 1 / Phase 2 | Recruiting | IDEAYA Biosciences | 262 | 2025-10-14 | 2026-07-09 |
| A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC) Tarlatamab, Durvalumab, Carboplatin - Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer | Phase 3 | Active not recruiting | Amgen | 350 | 2025-08-18 | 2026-09-08 |
| Durvalumab After Concurrent Chemoradiotherapy (cCRT) for Limited-stage Small-cell Lung Cancer (LS-SCLC) Small-cell Lung Cancer | Completed | Anhui Shi, MD | 45 | 2025-08-11 | 2026-02-12 | |
| Small Cell Lung Cancer Community Engagement to Eliminate Research Discepancies Small-cell Lung Cancer | Active not recruiting | Addario Lung Cancer Medical Institute | 22 | 2025-05-23 | 2026-08-04 | |
| Phase 2 Study of Fingolimod in Lung Cancers Fingolimod 0.5 milligram (mg) [Gilenya] - Non Small Cell Lung Cancer, Small-cell Lung Cancer | Phase 2 | Recruiting | Medical University of South Carolina | 38 | 2025-05-01 | 2026-03-30 |
| A Study of Hospital-at-Home for People Receiving Tarlatamab Hospital-at-Home/HAH - Small-cell Lung Cancer, Small Cell Lung Carcinoma | Not applicable | Recruiting | Memorial Sloan Kettering Cancer Center | 70 | 2025-04-23 | 2026-10-09 |
| A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit NN3201 - Gastrointestinal Stromal Tumors, Small-cell Lung Cancer | Phase 1 | Recruiting | Novelty Nobility, Inc. | 67 | 2025-02-03 | 2025-09-23 |
| a Study of QL1706 or QL1604 in Patients With Limited-stage Small Cell Lung Cancer After Chemoradiotherapy. Iparomlimab and Tuvonralimab (QL1706), placebo for QL1604, QL1604 - Small-cell Lung Cancer | Phase 3 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 636 | 2025-02-01 | 2025-02-11 |
| Study to Confirm Efficacy and Feasibility of Tarlatamab Treatment in Patients With Extensive Stage Small-cell Lung Cancer With Poor Performance Status Tarlatamab - Small-cell Lung Cancer | Phase 2 | Recruiting | AIO-Studien-gGmbH | 57 | 2025-01-01 | 2026-10-26 |
| A Study to Investigate the Efficacy and Safety of Ivonescimab Combined With Irinotecan Liposome as Second-line Regimen for SCLC ivonescimab, irinotecan liposome - Small-cell Lung Cancer | Phase 2 | Completed | Zhejiang Cancer Hospital | 60 | 2024-10-16 | 2026-08-27 |
| Intrathecal Pemetrexed for SCLC Patients With Refractory Brain Metastases or Leptomeninges Metastatic Intrathecal Pemetrexed - Small-cell Lung Cancer | Phase 2 | Unknown | Hunan Province Tumor Hospital | 80 | 2024-10-01 | 2024-09-19 |
| Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy BNT327 Dose Level 1 (DL1), BNT327 Dose Level 2 (DL2), Etoposide - Extensive-stage Small-cell Lung Cancer, Small-cell Lung Cancer | Phase 2 | Active not recruiting | BioNTech SE | 110 | 2024-08-05 | 2026-09-14 |
Showing 20 of 123. Sign in to see all of them.
Small Cell Lung Carcinoma (123) · Carcinoma, Non-Small-Cell Lung (26) · Carcinoma, Renal Cell (14) · Lung Neoplasms (14) · Stomach Neoplasms (14) · Carcinoma, Transitional Cell (13) · Uterine Cervical Neoplasms (13) · Carcinoma, Hepatocellular (11) · Melanoma (11) · Triple Negative Breast Neoplasms (11) · Squamous Cell Carcinoma of Head and Neck (10) · Ovarian Neoplasms (9) · Brain Neoplasms (8) · Breast Neoplasms (8) · Carcinoma, Merkel Cell (8)
Bronchial Neoplasms (123) · Carcinoma, Bronchogenic (123) · Lung Diseases (123) · Neoplasms by Site (123) · Respiratory Tract Diseases (123) · Respiratory Tract Neoplasms (123) · Thoracic Neoplasms (123) · Neoplasms (117) · Lung Neoplasms (109) · Neoplasms by Histologic Type (36) · Neoplasms, Glandular and Epithelial (34) · Carcinoma (28) · Urogenital Diseases (28) · Urogenital Neoplasms (28) · Digestive System Diseases (26)
Carboplatin (21) · Etoposide (19) · durvalumab (9) · atezolizumab (8) · pembrolizumab (8) · PM 01183 (7) · Irinotecan (6) · Topotecan (6) · Cisplatin (5) · Drug Therapy (4) · Gemcitabine (4) · Nivolumab (4) · Radiosurgery (4) · 130-nm albumin-bound paclitaxel (3) · Paclitaxel (3)
Washington University School of Medicine (4) · Chinese Academy of Medical Sciences (3) · MacroGenics (3) · Memorial Sloan Kettering Cancer Center (3) · Shanghai Pulmonary Hospital, Shanghai, China (3) · AIO-Studien-gGmbH (2) · Amgen (2) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (2) · Fox Chase Cancer Center (2) · H. Lee Moffitt Cancer Center and Research Institute (2) · Hunan Province Tumor Hospital (2) · Incyte Corporation (2) · Jiangsu HengRui Medicine Co., Ltd. (2) · Norwegian University of Science and Technology (2) · Peng Zhang (2)
United States (66) · China (42) · Spain (14) · France (13) · Poland (11) · Australia (10) · Belgium (10) · Germany (10) · South Korea (10) · Italy (9) · United Kingdom (9) · Canada (7) · Greece (7) · Turkey (Türkiye) (7) · Hungary (6)
Alberto A Chiappori, MD (2) · ShengFa Su, PhD,MD (2) · Abraham Wu, MD (1) · Afshin Dowlati, MD (1) · Anish Thomas, MD (1) · Ashish Saxena, MD (1) · Ashley Ward, MD (1) · Benjamin Lok, MD (1) · Bo Lu, MD (1) · Brian Henick, MD (1) · Christine Auberle, M.D. (1) · Christine Bestvina, MD (1) · Christine Lovly, MD PhD (1)
PMID 42580817, PMID 10561263, PMID 25230595, PMID 28581401, PMID 30280641, PMID 32188425, PMID 32385714, PMID 32819975, PMID 33166719, PMID 33234490, PMID 33358484, PMID 33446664, PMID 34726887, PMID 36180086, PMID 36252599, PMID 36727741, PMID 36907793, PMID 37857711, PMID 37977903, PMID 38329180, PMID 39462179, PMID 39489541, PMID 39941812, PMID 40210967, PMID 40473449, PMID 40481574, PMID 40934933, PMID 42444902, PMID 42834100
2019 (2), 2023 (2), 2017 (1), 2018 (1), 2025 (1), 5UG1CA189824-08 (1), P30CA093373 (1), R01CA273216 (1)